mRNA Rotavirus Vaccine for Stable Multiserotype Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current rotavirus vaccines face reduced efficacy in developing countries due to factors like pre-existing antibodies, malnutrition, and prevalent gastrointestinal infections, necessitating a need for a temperature-stable, cost-effective vaccine effective against multiple serotypes, especially suitable for parenteral delivery.
Innovation Solution
Development of an mRNA-based vaccine composition that includes specific mRNA sequences encoding rotavirus epitopes, stabilized with 5'-CAP structures and poly(A) tails, allowing for parenteral administration and enhanced immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live-attenuated rotavirus vaccines are used, then immunity is induced, but efficacy is reduced in developing countries due to pre-existing antibodies, malnutrition, and gastrointestinal infections
Solution Approach 1:
The patent extracts only the essential immunogenic components (VP6 and VP8* proteins) from the complete rotavirus structure to create a subunit vaccine. This extraction approach eliminates the vulnerability to pre-existing antibodies and gastrointestinal infections that affect live-attenuated vaccines, while maintaining the ability to induce protective immunity against rotavirus.
Solution Approach 2:
The patent focuses on specific local components (VP6 capsid protein and VP8* spike protein) that are most critical for immune recognition and protection. By concentrating on these specific proteins rather than using the entire virus, the vaccine achieves reliable efficacy while avoiding the harmful effects that reduce live vaccine performance in developing countries.
2Stability of the object's composition
If temperature-stable vaccine formulations are developed, then storage and distribution without cold chains becomes possible, but manufacturing complexity may increase
Solution Approach 1:
The patent employs a recombinant protein expression system in insect cells that produces stable vaccine antigens capable of withstanding temperature variations. This approach creates a formulation that is inherently more stable and less dependent on cold chain infrastructure, making it suitable for use in resource-limited settings despite the complexity of recombinant manufacturing.
3Adaptability or versatility
If subunit vaccines with specific epitopes are used, then cross-protection against multiple serotypes is achieved, but manufacturing precision requirements increase
Solution Approach 1:
The patent designs the vaccine to include VP6 and VP8* proteins that are highly conserved across multiple rotavirus serotypes. This universal approach allows a single vaccine formulation to provide cross-protection against different serotypes (including G1-G4 and P[4], P[6], P[8]), achieving versatility without requiring multiple separate vaccines.
Solution Approach 2:
The patent utilizes the high conservation of amino acid sequences in VP6 and VP8* across different serotypes to create a broadly protective vaccine. By targeting these conserved regions rather than variable epitopes, the vaccine achieves cross-serotype efficacy while simplifying the manufacturing challenge of covering multiple strains.
Data Source
AI summary
The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.